MyPeptideMatchOverview
PT-141 (bremelanotide) is an FDA-approved medication sold under the brand name Vyleesi. It is a melanocortin receptor agonist approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike many peptides discussed in longevity or performance contexts, PT-141 has a clear FDA approval and a defined place in clinical practice. People seek it for low libido that causes distress and is not explained by other medical or relationship issues. It is prescribed by healthcare providers and can be compounded in certain circumstances as a component of the approved drug.
PT-141 works through pathways involved in sexual desire and arousal. It is not a hormone; it acts on receptors in the brain. Evidence from clinical trials supports its use for HSDD in the approved population.
How It Works (Mechanism of Action)
PT-141 activates melanocortin receptors (e.g., MC3R and MC4R) in the central nervous system. These receptors are involved in the regulation of sexual function and desire. By stimulating them, PT-141 can increase sexual desire and arousal in some patients. The exact mechanism in HSDD is still being elucidated, but the clinical effect is well documented in trials.
Primary Uses
Hypoactive Sexual Desire Disorder (HSDD)
Vyleesi is approved for HSDD in premenopausal women—persistently low sexual desire that causes distress and is not due to a co-existing medical or psychiatric condition or relationship problem. It is used on an as-needed basis, with injection at least 45 minutes before anticipated sexual activity. It is not approved for men or for other indications.
